Oryza Pharmaceuticals
Oryza Pharmaceuticals is a Shenzhen-based, privately held pharmaceutical technology company that develops and licenses drug delivery platforms (oral controlled-release, transdermal, long-acting injectable, oral soluble film) to global pharmaceutical companies in China and the United States.
- Company typePrivate
- Founded2016
- HeadquartersShenzhen, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Oryza Pharmaceuticals firmographics
Firmographics- Name
- Oryza Pharmaceuticals
- Legal name
- 深圳市瑞华制药技术有限公司
- Website
- https://oryzapharma.com.cn
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oryza Pharmaceuticals is a Shenzhen-based, privately held pharmaceutical technology company that develops and licenses drug delivery platforms (oral controlled-release, transdermal, long-acting injectable, oral soluble film) to global pharmaceutical companies in China and the United States.
- Ownership category
- akta.pro rank
Oryza Pharmaceuticals industry classification
Industry- Product category
- Pharmaceutical Drug Delivery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industries
- Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ), Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Oryza Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Shenzhen
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Oryza Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Development and Licensing: The company develops high-end generic drugs, improved new drugs, and drug delivery technologies, licensing them to pharmaceutical companies globally
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Oryza Pharmaceuticals product offering
Product offeringCore offering
Oryza Pharmaceuticals develops, manufactures, and licenses advanced drug delivery technology platforms and high-end pharmaceutical formulations, including controlled-release generics, first-to-market generic drugs, and improved new drugs. The company operates four proprietary technology platforms — oral controlled-release, transdermal patch, long-acting injectable, and oral soluble film — collectively covering 30 distinct drug delivery technologies used to challenge patents, shorten R&D timelines, and improve regulatory approval success for global pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Products and services
- Oral Controlled Release Drug Delivery Platform (口服缓控释制剂技术平台) A drug delivery technology platform for oral controlled-release formulations, enabling sustained and continuous release of medications over extended periods to improve bioavailability and dosing convenience; intended for global pharmaceutical partners developing complex generics and improved new drugs.
- Transdermal Patch Controlled Release Platform (透皮贴剂缓控释制剂技术平台) A transdermal patch technology platform enabling sustained drug delivery through skin absorption; targeted at pharmaceutical partners developing non-oral controlled-release products.
- Long-Acting Injectable Platform (注射用长效制剂技术平台) An injection-based long-acting drug delivery platform for extended-release injectable formulations; intended for pharmaceutical partners developing chronic-disease or depot-formulation products.
- Oral Soluble Film Platform (口溶膜制剂技术平台) A fast-dissolving oral film technology platform providing a convenient drug administration format; intended for pharmaceutical partners seeking patient-friendly dosage forms.
Companies that use Oryza Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Oryza Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Oryza Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Reflexiv+ (美国Reflexiv+公司)coreOryza Pharmaceuticals partnered with US-based Reflexiv+ to jointly develop a series of sports fitness maintenance and rehabilitation products enabled by formulation and delivery technologies, including products based on Traditional Chinese Medicine and Miao-Dong herbal medicine.
- 贵州中科 (Guizhou Zhongke)coreOryza Pharmaceuticals formed a strategic partnership with Guizhou Zhongke (Guizhou Zhongke Molecular Biotechnology) to advance modernization of traditional Chinese medicine, expanding the company's reach in the TCM field.
Scale indicators1 record
Oryza Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Catalent: Global CDMO and drug delivery specialist offering oral, injectable, and topical formulation platforms to pharma partners. Directly comparable to Oryza in the drug delivery technology and formulation development space, though at vastly larger scale.
- West Pharmaceutical Services: Established provider of drug delivery technologies including injectable delivery systems, elastomeric components, and formulation services. Comparable in drug delivery device and formulation platform offerings.
- Becton, Dickinson and Company (BD Pharmaceutical Systems): Large medical technology company with pharmaceutical systems segment providing prefillable syringes, injection devices, and drug delivery solutions. Comparable in injectable and other delivery platforms serving pharma partners.
Direct peers
- Kindeva Drug Delivery: Specialty drug delivery CDMO offering sustained-release, transdermal, and inhalation delivery platforms. Direct peer in formulation technology licensing and development services.
- LTS Lohmann Therapie-Systeme: Specialized drug delivery company focused on transdermal therapeutic systems and oral thin film technologies. Highly comparable in transdermal patch and oral soluble film platform focus.
- AdhexPharma: European specialty pharma focused on transdermal drug delivery patches and oral thin films. Comparable platform-level technology focus and licensing business model.
Regional players
- Luye Pharma Group: China-based pharmaceutical company with strong long-acting injectable platform (e.g., Risperidone LAI). Comparable as a Chinese pharma leveraging proprietary drug delivery technology for both domestic and international markets.
- Yiling Pharmaceutical: Major Chinese TCM-focused pharmaceutical company modernizing traditional Chinese medicine formulations. Comparable through the Guizhou Zhongke partnership angle and TCM modernization exposure.
Emerging players
- Laboratorios Farmacéuticos Rovi: Spanish specialty pharma with proprietary long-acting injectable platform (ISM technology) and strong position in heparin and contrast media. Comparable as a formulation-technology-driven pharma licensing platform with international ambitions.
- Aucta Pharmaceuticals: Emerging Chinese specialty pharma focused on complex generics and 505(b)(2) drug development with proprietary formulation technologies. Comparable scale and stage as a Chinese drug delivery/formulation technology company targeting US markets.
Market position
Customer concentration
Oryza Pharmaceuticals social profiles
Digital presenceOryza Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oryza Pharmaceuticals leadership team
Management profileNumber of profiles
Oryza Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oryza Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oryza Pharmaceuticals
What does Oryza Pharmaceuticals do?
Oryza Pharmaceuticals develops, manufactures, and licenses advanced drug delivery technology platforms and high-end pharmaceutical formulations, including controlled-release generics, first-to-market generic drugs, and improved new drugs. The company operates four proprietary technology platforms — oral controlled-release, transdermal patch, long-acting injectable, and oral soluble film — collectively covering 30 distinct drug delivery technologies used to challenge patents, shorten R&D timelines, and improve regulatory approval success for global pharmaceutical partners.
Is Oryza Pharmaceuticals a public or private company?
Oryza Pharmaceuticals is a private company. It is classified as unknown and is currently operating.
When was Oryza Pharmaceuticals founded?
Oryza Pharmaceuticals was founded in 2016. It employs 11 to 50 people.
Where is Oryza Pharmaceuticals based?
Oryza Pharmaceuticals is headquartered in Shenzhen, China, in the Asia region.
How does Oryza Pharmaceuticals make money?
One revenue line is on record: drug Development and Licensing.
Who are Oryza Pharmaceuticals's main competitors?
Broad incumbents on record are Catalent, West Pharmaceutical Services and Becton, Dickinson and Company (BD Pharmaceutical Systems). Direct peers are Kindeva Drug Delivery, LTS Lohmann Therapie-Systeme and AdhexPharma. Regional players are Luye Pharma Group and Yiling Pharmaceutical. Emerging players are Laboratorios Farmacéuticos Rovi and Aucta Pharmaceuticals.
Does Oryza Pharmaceuticals have an API?
No public API is recorded for Oryza Pharmaceuticals.
What industry is Oryza Pharmaceuticals in?
Oryza Pharmaceuticals's product category is Pharmaceutical Drug Delivery. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAJ, Generic ANDA/Regulatory Affairs & Submissions. Its NAICS code is 325412 and its SIC code is 2834.